[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615258":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":25,"responsibleParty":39,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":43,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Cohort 1",null,"Patients diagnosed with Metastatic Castration-Resistant Prostate Cancer (mCRPC) previously treated with at least one ARPI with or without taxane regimens.",{"label":13,"type":10,"description":14,"interventionNames":10},"Cohort 2","Patients diagnosed with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).",[16],{"name":17,"affiliation":17,"role":18},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[20,24],{"name":17,"role":21,"phone":22,"phoneExt":10,"email":23},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":17,"role":21,"phone":10,"phoneExt":10,"email":10},[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":10},"Novartis Investigative Site","RECRUITING","Shanghai","Shanghai Municipality","China","CN",{"type":34,"coordinates":35},"Point",[36,37],121.45806,31.22222,{"lat":37,"lon":36},{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100615258","real-world-use-of-lutetium-177lu-vipivotide-tetraxetan-in-chinapsmareal-cn-100615258",false,"NCT07290270","Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)","Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan Injection in Metastatic Prostate Cancer: an Observational, Multicenter, Prospective Cohort Study in China (PSMAreal CN)","PSMAreal","Inclusion Criteria:\n\nAdult male patients diagnosed with mCRPC or mHSPC Initiating lutetium (177Lu) vipivotide tetraxetan treatment by treating physician as per local label. After treatment decision enrollment is allowed before date of cycle 1 or within 2 weeks after the date of cycle 1 Written ICF must be obtained prior to any data collection Participants must have adequate organ function following Society of Nuclear Medicine and Molecular Imaging (SNMMI) consensus (Hope et al., 2023)\n\nExclusion Criteria:\n\nSimultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with lutetium (177Lu) vipivotide tetraxetan during the study period\n\nOther protocol-defined inclusion \u002F exclusion criteria may apply","MALE","18 Years","99 Years",{"count":53,"type":54},170,"ESTIMATED","OBSERVATIONAL","This non-interventional, observational, multicenter, prospective cohort study is designed to investigate the treatment patterns of mPC patients treated with lutetium (177Lu) vipivotide tetraxetan, as well as their clinical outcomes, real-world characteristics, and quality of life during the treatment period and up to one year after treatment completion.",[58],"Metastatic Prostate Cancer",[58,60,61,62,63,31],"Metastatic Castration-Resistant Prostate Cancer","Metastatic Hormone-Sensitive Prostate Cancer","Lutetium (177Lu) vipivotide tetraxetan Injection","Non-interventional Study","2026-03-25",{"date":66,"type":67},"2026-03-30","ACTUAL",{"date":69,"type":67},"2026-02-04",{"date":71,"type":54},"2029-08-31",{"name":17,"class":6},1]